Home  |  Contact

UniProtKB/Swiss-Prot Q04637: Variant p.Gly686Cys

Eukaryotic translation initiation factor 4 gamma 1
Gene: EIF4G1
Variant information

Variant position:  686
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Unclassified
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Glycine (G) to Cysteine (C) at position 686 (G686C, p.Gly686Cys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to medium size and polar (C)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  Found in patients with Parkinson disease; unknown pathological significance.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  686
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1599
The length of the canonical sequence.

Location on the sequence:   FTPSFANLGRTTLSTRGPPR  G GPGGELPRGPAGLGPRRSQQ
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         FTPSFANLGRTTLSTRGPPRGGPGGELPRGPAGLGPRRS-QQ

Mouse                         FTPSFANLGRPALSNRGPPRGGPGGELPRGPAGLGPRRS-Q

Rabbit                        FTPSFANLGRPALSSRGPPRGGPGGELPRGAAGLGPRRSLQ

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 1599 Eukaryotic translation initiation factor 4 gamma 1
Domain 565 – 792 MIF4G
Region 682 – 1085 eIF3/EIF4A-binding
Modified residue 685 – 685 Omega-N-methylarginine
Modified residue 694 – 694 Omega-N-methylarginine
Alternative sequence 696 – 696 P -> PQ. In isoform 7 and isoform 8.
Mutagenesis 682 – 682 G -> AVWRE. Reduced cleavage by protease 2A from human rhinovirus 2.


Literature citations

Translation initiator EIF4G1 mutations in familial Parkinson disease.
Chartier-Harlin M.C.; Dachsel J.C.; Vilarino-Guell C.; Lincoln S.J.; Lepretre F.; Hulihan M.M.; Kachergus J.; Milnerwood A.J.; Tapia L.; Song M.S.; Le Rhun E.; Mutez E.; Larvor L.; Duflot A.; Vanbesien-Mailliot C.; Kreisler A.; Ross O.A.; Nishioka K.; Soto-Ortolaza A.I.; Cobb S.A.; Melrose H.L.; Behrouz B.; Keeling B.H.; Bacon J.A.; Hentati E.; Williams L.; Yanagiya A.; Sonenberg N.; Lockhart P.J.; Zubair A.C.; Uitti R.J.; Aasly J.O.; Krygowska-Wajs A.; Opala G.; Wszolek Z.K.; Frigerio R.; Maraganore D.M.; Gosal D.; Lynch T.; Hutchinson M.; Bentivoglio A.R.; Valente E.M.; Nichols W.C.; Pankratz N.; Foroud T.; Gibson R.A.; Hentati F.; Dickson D.W.; Destee A.; Farrer M.J.;
Am. J. Hum. Genet. 89:398-406(2011)
Cited for: VARIANTS PARK18 VAL-502 AND HIS-1205; VARIANTS SER-71; ALA-161; CYS-311; VAL-432; 466-GLY--ALA-468 DEL; CYS-686; VAL-806; SER-829; ARG-1164; TRP-1197; ALA-1229; PRO-1233 AND SER-1257;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.